Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients
- PMID: 23143606
- PMCID: PMC11824757
- DOI: 10.1007/s00432-012-1345-5
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients
Abstract
Background: Breast cancer patients regularly undergo adjuvant chemotherapies following surgery. However, these treatments are largely associated with chemotherapeutic toxicities ranging from nausea to severe myelosuppression. In this investigation, we examined the effects of four SNPs in NR1I2, CYP3A4 and CYP3A5 genes on chemotherapy-induced severe neutropenia in 311 female Chinese breast cancer patients undergoing a standard adjuvant chemotherapy regimen.
Methods: Patients were monitored for adverse reactions throughout the treatment, then divided into "none or mild" (80 %) or "severe" (20 %) toxicity groups according to whether they suffered grade 4 neutropenia defined as having an absolute neutrophil counts (ANC) of less than 0.5 × 10(9)/L anytime during the treatment. DNA was extracted from patients' peripheral blood samples, then genotyped using allele-specific Tm-shift PCR and melting analysis.
Results: Logistic regression revealed that rs776746 or CYP3A5*3 strongly associated with grade 4 neutropenia (OR = 2.56, P = 0.023) after adjustment for covariates, one of which more significant factor was baseline ANC (OR = 0.68, P = 0.020). Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancer patients with normal baseline ANC (≥2.0 × 10(9)/L). These carriers of A-allele have 3.14-fold increased risk of developing severe neutropenia (P = 0.004).
Conclusion: Our results suggested that polymorphisms in CYP3A5 might be useful pharmacogenetic markers for the prediction of severe neutropenia during chemotherapy, however, only after screening patients by their baseline ANC in the presence of gene-environmental interaction. We demonstrate an approach of pharmacogenetic analysis, in which the genetic data should be analyzed in the perspective of other clinical parameters.
Conflict of interest statement
None.
Similar articles
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866378 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.Int J Cancer. 2016 Nov 1;139(9):1930-5. doi: 10.1002/ijc.30236. Epub 2016 Jul 4. Int J Cancer. 2016. PMID: 27312107 Free PMC article. Clinical Trial.
-
Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.Front Pharmacol. 2018 Mar 13;9:158. doi: 10.3389/fphar.2018.00158. eCollection 2018. Front Pharmacol. 2018. PMID: 29593529 Free PMC article.
-
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer.Cancer Chemother Pharmacol. 2018 Dec;82(6):953-960. doi: 10.1007/s00280-018-3685-6. Epub 2018 Sep 14. Cancer Chemother Pharmacol. 2018. PMID: 30218151 Free PMC article.
-
Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy.Front Pharmacol. 2020 Apr 15;11:445. doi: 10.3389/fphar.2020.00445. eCollection 2020. Front Pharmacol. 2020. PMID: 32351390 Free PMC article. Review.
-
Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201. BMC Cancer. 2014. PMID: 24641830 Free PMC article.
References
-
- Anglicheau D, Legendre C, Beaune P, Thervet E (2007) Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8(7):835–849 - PubMed
-
- Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265. doi:10.1093/bioinformatics/bth457 - PubMed
-
- Beith J, Goh B, Yeo W, Sullivan A, Lim S, Zhong S, Rivory L (2002) Interethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. In: Proceedings of American Society of Clinical Oncology Annual Meeting: J Clin Oncol 21:64a, #252
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical